CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin and
natriuretic peptide receptor systems, announced today that it will
be presenting at the H.C. Wainwright & Co., 22nd
Annual Global Investment Conference on Monday, September 14, 2020 at 4:00 p.m. EDT. The conference will be held
virtually.
Carl Spana, Ph.D., President and
Chief Executive Officer of Palatin Technologies, will provide an
update on Palatin's corporate and development programs.
The presentation will be webcast and can be accessed by logging
on to the "Investor/Webcasts" section of Palatin's website at
http://www.palatin.com or by clicking the following link:
https://wsw.com/webcast/hcw7/ptn/1491682. The webcast will be
available for 90 days.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is a specialized biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin and natriuretic peptide
receptor systems, with targeted, receptor-specific product
candidates for the treatment of diseases with significant unmet
medical need and commercial potential. Palatin's strategy is to
develop products and then form marketing collaborations with
industry leaders in order to maximize their commercial potential.
For additional information regarding Palatin, please visit
Palatin's website at www.Palatin.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-to-present-at-the-hc-wainwright--co-22nd-annual-global-investment-conference-301128027.html
SOURCE Palatin Technologies, Inc.